All Articles

As single-agent immunotherapies continue to show promising results, the challenge is now to determine which combination regimens with immunotherapies can improve outcomes.

Direct Oral Anticoagulants: New Standard of Care for VTE in Patients with Cancer?

Highlights From ASH

April 2018 Vol 9, No 4

Direct oral anticoagulants (DOACs) may replace low molecular weight heparin (LMWH) as standard of care for management of venous thromboembolism (VTE) in cancer patients, judging by the results of 2 randomized trials presented at ASH 2017.

CAR T-Cell Therapy Makes Significant Inroads in Lymphoma: Kymriah and Yescarta Show Durable Remissions

Highlights From ASH

April 2018 Vol 9, No 4

CD19-directed chimeric antigen receptor (CAR) T-cell therapy continues to show excellent and durable responses in patients with lymphoma who have no other treatment options.

A Nurse Navigator’s Perspective on CDK4/6 Inhibitors

By Sharon S. Gentry, MSN, RN, HON-ONN-CG, AOCN, CBCN

Breast Cancer, Perspectives

Rx Profiler – Abemaciclib (Verzenio™), a Novel CDK4/6 Inhibitor, in the Treatment of Hormone Receptor–Positive, HER2-Negative Advanced Breast Cancer

Metastatic breast cancer (MBC) or advanced breast cancer (ABC) signifies that cancer has spread to a distant organ site, either as a progression or a recurrence after a patient has first been diagnosed with an earlier stage of breast cancer. Alternatively, in the case of de novo MBC, MBC or ABC is staged as being metastatic or stage IV at diagnosis.

A Pharmacist’s Perspective on CDK4/6 Inhibitors

By Robert Wolf, PharmD

Breast Cancer, Perspectives

Rx Profiler – Abemaciclib (Verzenio™), a Novel CDK4/6 Inhibitor, in the Treatment of Hormone Receptor–Positive, HER2-Negative Advanced Breast Cancer

Breast cancer is the most common cancer in women and remains a leading cause of cancer-related morbidity, mortality, and resource utilization. For patients with advanced breast cancer, prognosis remains especially suboptimal, primarily because of acquired pharmacologic resistance.

A Payer’s Perspective on CDK4/6 Inhibitors

By Kenneth L. Schaecher, MD, FACP, CPC

Breast Cancer, Perspectives

Rx Profiler – Abemaciclib (Verzenio™), a Novel CDK4/6 Inhibitor, in the Treatment of Hormone Receptor–Positive, HER2-Negative Advanced Breast Cancer

As pointed out in this monograph, breast cancer remains a significant issue for patients and payers, as it is one of the highest-prevalence cancers and, thus, results in high costs.

Breaking News: Sellas Announces Promising Data on NeuVax in Combination with Herceptin in HER2 1+/2+ Breast Cancer

Breast Cancer, Web Exclusives

Web Exclusives

NeuVax + Herceptin may provide a clinically meaningful benefit to breast cancer patients with low to intermediate HER2-expression.

Nursing Research: A Vital Component to Improving Patient Care

By Lillie D. Shockney, RN, BS, MAS, HON-ONN-CG

Letters from Lillie, Research/Quality/Performance Improvement

March 2018 Vol 9, No 3

This is your year to conduct research and share your findings. AONN+ and the AQUIRE committee can help you to reach this goal.

Fear of Cancer Recurrence in Gynecologic Cancer Survivors: An Overview

By Annamma Sam, PhD, APRN, WHNP-BC

Original Research, Psychosocial Support Services/Assessment, Survivorship

March 2018 Vol 9, No 3

Studies indicate that a high fear of cancer recurrence may be correlated with posttraumatic stress disorder in long-term survivors. A better understanding of this fear in cancer survivors can help clinicians manage this problem effectively.

Transforming Healthcare Through Research and Reporting

By Cheryl Bellomo, MSN, RN, HON-ONN-CG, OCN

Research/Quality/Performance Improvement

March 2018 Vol 9, No 3

Cheryl Bellomo, MSN, RN, OCN, ONN-CG, encourages navigators to conduct research and report findings to enrich the navigation literature and promote best practices.

All Articles

Page 208 of 283

Connect with Us

Subscribe Today!

I'd like to receive:

Please enter your mailing address.